The Ministry of Health, Labor and Welfare (MHLW) on September 6 ordered Amgen Astellas BioPharma to revise its label for the osteoporosis drug Evenity (romosozumab) in order to call physicians’ attention to the risks of cardiovascular events. In its warnings…
To read the full story
Related Article
- Takeda Launches Zafatek 25 mg for Patients with Renal Dysfunction
December 4, 2019
- Evenity under PMDA Risk Review
August 27, 2019
REGULATORY
- Japan to Clarify Non-Clinical Data Waivers for Repurposed Drugs, Ease Sakigake Rules
July 24, 2026
- Share of Negative-Margin WPPs Rises to 6.9%, Wholesalers Cite Communication Gap
July 24, 2026
- MHLW Unveils Preventive Healthcare Plan Focused on Dementia, Other Areas
July 24, 2026
- MHLW Eyes Limited Charge Exemptions for OTC-Like Topical Drugs
July 24, 2026
- MHLW Panel Voices Disappointment over Efluelda Launch Delay
July 24, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…





